Gabon

Sanofi-aventis - DNDi Malaria Medicine

In April 2005, sanofi-aventis signed an agreement with Drugs for Neglected Diseases initiative (DNDi) to develop a new medicine against malaria, in response to a call from the World Health Organization (WHO) for malaria be treated by drug combinations to combat resistance. DNDi and sanofi-aventis have developed a fixed-dose combination (FDC) of two antimalarial compounds, artesunate and amodiaquine (ASAQ) that is easier to use and more affordable than any other combination currently available.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

PATH Malaria Vaccine Initiative (MVI)

MVI works to link government, industry, and academia partners with field trial sites in malaria endemic countries as early as feasible in the development process.

Novartis Coartem

Coartem is the first World Health Organization-prequalified fixed-dose, artemisinin-based combination therapy (ACT) antimalarial, approved by stringent regulatory authorities and on the WHO Model List of Essential Medicines. Coartem is fast-acting and cures over 97% of patients after a 3-day treatment course. Coartem combines artemether, a derivative of artemisinin (from the Chinese medicinal plant Artemisia annua), with a synthetic substance, lumefantrine, which has not been used as a monotherapy.

Merck & Co., Inc. HIV/AIDS Programs - Africa

In 2009, with support from The Merck Company Foundation, the Earth Institute at Columbia University launched a community health worker training program to strengthen community health services for over 400,000 people in 10 African countries as part of the Millennium Villages project. The initiative aims to develop a professional cadre of 800 community health workers to fill a critical gap in primary healthcare provision for rural communities throughout Africa.

Leprosy Elimination

Novartis is providing free treatment for leprosy patients worldwide through its multi-drug therapy.

LEEM Quality Control Program

Counterfeit and substandard medicines are a major threat to health in developing countries, many of which lack the technical resources to identify inferior quality medicines. To help alleviate this situation, the association representing the R&D pharmaceutical industry in France, Les Entreprises du Medicament (LEEM), started a program in 2006 to allow developing countries to send samples of suspect medicines to France for analysis. To ensure impartiality, the LEEM pays for samples to be analyzed by an independent expert body, the Central Humanitaire Medico Pharmaceutique (CHMP).

Global Pharma Health Fund

The Global Pharma Health Fund e.V. (GPHF) is a charitable organization initiated and funded exclusively by donations from Merck KGaA, Darmstadt Germany. In 2007, it took over the work of the former German Pharma Health Fund, which was set up in 1985. The organization aims to improve health care in the context of development assistance, in particular the use of the GPHF-Minilab in the fight against counterfeit drugs.

Boehringer Ingelheim Access

Boehringer Ingelheim offers its product Viramune® for single-dose use in the prevention of mother-to-child transmission for free and/or reduced prices.

Zambia Ministry of Health

Pages